BioSpace News Archive

IMUNON, Inc. announces that the Company will host a conference call at 11:00 a.m. EDT on Thursday, May 11, 2023 to discuss financial results for the first quarter ended March 31, 2023.

Juno Pharmaceuticals Canada, a Canadian specialty pharmaceutical company, announced it has received approval from Health Canada to import ketamine solution for injection pursuant to Health Canada’s exceptional importation and sale guidelines.

Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that it will report its financial results for the first quarter ended March 31, 2023, on Thursday, May 11, 2023.

AmerisourceBergen, a global healthcare company, has announced a strategic partnership with SteadyMD, a B2B telehealth infrastructure provider that powers high-quality telehealth patient experiences for leaders and innovators in healthcare.

Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) Spago Nanomedical AB (publ) announces today that principal investigator Dr Ligita Jokubkiene is participating in the 15th World Congress on Endometriosis scientific conference where she will present observations from the ongoing phase IIa clinical study SPAGOPIX-02 evaluating the contrast agent SN132D in endometriosis.

Centinel Spine®, LLC, a leading global medical device company addressing cervical and lumbar spinal disease by providing the most robust and clinically-proven total disc replacement technology platform in the world, announced the 2023 nomination of prodisc for the Prix Galien Award in the ‘Best Medical Technology’ category.

Iterative Health announced the upcoming commercial availability of SKOUT, real-time artificial intelligence for polyp detection, in the second quarter of 2023.

Veracyte, Inc. (Nasdaq: VCYT) announced findings from a large-scale, systematic literature review showing that TERT promoter gene mutations in thyroid nodules deemed indeterminate by cytopathology are rare, but have a high risk of malignancy and, in certain cases, are associated with aggressive tumor behavior.

Cloud DX Inc. (TSXV: CDX) (OTCQB: CDXFF) (“Cloud” or the “Corporation”), is announcing that, further to its press release dated May 1, 2023 in respect of its application to the relevant securities regulatory authorities for a management cease trade order (“MCTO”), that the Ontario Securities Commission has granted MCTO.

BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCF) has surpassed 2,000 verified online reviews for its flagship product, VINIA, following the launch of the first major 2023 marketing campaign, “Real Stories,” focusing on the red grape-based supplement’s impact on customers’ lives.